Aerosolized furosemide in wheezy infants: a negative report

Area of Science:

• Pediatric Pulmonology
• Respiratory Medicine
• Clinical Pharmacology

Background:

• Infant wheezing is a common respiratory issue.
• Furosemide is a diuretic, but its inhaled form is explored for respiratory conditions.
• Evidence for inhaled furosemide's efficacy in infants is limited.

Purpose of the Study:

• To evaluate the therapeutic effects of aerosolized furosemide in infants with acute wheezing.
• To assess the impact of inhaled furosemide on airway resistance and functional residual capacity in wheezing infants.

Main Methods:

• Double-blind, placebo-controlled study design.
• Part A: 28 acutely wheezing infants received 10 mg aerosolized furosemide or placebo, assessing clinical score.
• Part B: 20 intermittently wheezing infants received 10 mg aerosolized furosemide or placebo during symptom-free periods, measuring airway resistance and functional residual capacity.

Main Results:

• No significant improvement in clinical scores was observed in infants receiving aerosolized furosemide (Part A).
• Inhaled furosemide did not alter airway resistance or functional residual capacity in symptom-free infants (Part B).
• No therapeutic effects were found during or after furosemide inhalation in either study group.

Conclusions:

• Aerosolized furosemide at 10 mg demonstrated no therapeutic benefit for acute or intermittent wheezing in infants.
• The findings do not support the use of inhaled furosemide for managing wheezing symptoms in this pediatric population.
• Further research may be needed to explore alternative inhaled therapies for infant wheezing.